Company
Biometec GmbH - Company of biomedical technologies GmbH is a German biotech company in the BioRegio Greifswald-Rostock on the Baltic coast of north eastern Germany.
The company was founded in 1992, is an outsourcing from the University of Greifswald and is centred in the BioTechnikum in Greifswald.
The company is engaged in the development, production and distribution of research products for infection biology especially CD14, LBP and antibodies. In addition biometec offers a variety of laboratory and immunbiological services for academic institutes as well as pharmaceutical and biotechnological companies.
The highly motivated team consists of one scientist and two technical assistants. All staffs haven long time experience in generation of monoclonal and polyclonal antibodies, as well as in assay development, cell culture, animal studies, and immunological studies.
Management:
Dr. Sabine Witt, Managing Director (CEO, CSO, CFO)
- Since 1992, studied biology at university of Greifswald with additional specification in Immunology;
- long time experience in antibody and protein generation as well as company management.
Certification
biometec achieves ISO 9001:2015 certification
In Cooperation With
References
Schütt, C. et al. (1999): Implications for a general role of LPS binding proteins (CD14, LBP) in combating bacterial intections. J. Endotoxin Research 5, 75-80
Schütt, C.; Witt, S.; Grunwald, U.; Stelter, F.; Schilling, T.; Fan, X.; Marquart, B.; Bassarab, P.; Krüger, C. (1995): Epitope mapping of CD14 glycoprotein in Leukocyte typing V, ( L. Bournsell, W. Gilks, J. M. Harlan, T. Kishimoto, C. Morimoto, J. Ritz, S. F. Schossmanns, S. Shaw, R. Silverstein, T. Springer, T. F. Tedder, R. F. Todd, eds), Oxford University Press, Oxford, 785-788
Stelter, F.; Bernheiden, M.; Menzel, R.; Jack, R. S.; Witt, S.; Fan, X.; Pfister, M.; Schütt, C. (1997): Mutation of amino acids 39-44 of human CD14 abrogates binding of lipopolysaccharide and Escherichia coli. Eur. J. Biochem, 243, 100-109
